TheraCell AI
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
An AI-driven biotech platform optimizing cell therapy development for regenerative medicine.
Regenerative MedicineOrthopedicsAutoimmune
Technology Platform
An artificial intelligence and machine learning platform designed to optimize the development and manufacturing of cell therapies by predicting key quality and potency attributes.
Funding History
2Total raised:$100M
Series B$15M
Series A$85M
Opportunities
Potential to significantly reduce the time, cost, and failure rate of developing complex cell-based regenerative medicines.
Risk Factors
Early-stage platform risk; unproven ability to generate clinically validated cell therapy candidates that outperform traditional development methods.
Competitive Landscape
Part of the competitive AI-for-biotech landscape but focused specifically on solving cell therapy's unique development and manufacturing challenges.